IL156339A0 - Indazolyl-substituted pyrroline compounds as kinase inhibitors - Google Patents

Indazolyl-substituted pyrroline compounds as kinase inhibitors

Info

Publication number
IL156339A0
IL156339A0 IL15633901A IL15633901A IL156339A0 IL 156339 A0 IL156339 A0 IL 156339A0 IL 15633901 A IL15633901 A IL 15633901A IL 15633901 A IL15633901 A IL 15633901A IL 156339 A0 IL156339 A0 IL 156339A0
Authority
IL
Israel
Prior art keywords
indazolyl
kinase inhibitors
kinase
substituted pyrroline
compounds
Prior art date
Application number
IL15633901A
Other languages
English (en)
Original Assignee
Ortho Mcneil Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho Mcneil Pharm Inc filed Critical Ortho Mcneil Pharm Inc
Publication of IL156339A0 publication Critical patent/IL156339A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
IL15633901A 2000-12-08 2001-12-06 Indazolyl-substituted pyrroline compounds as kinase inhibitors IL156339A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25416600P 2000-12-08 2000-12-08
PCT/US2001/047689 WO2002046183A2 (en) 2000-12-08 2001-12-06 Indazolyl-substituted pyrroline compounds as kinase inhibitors

Publications (1)

Publication Number Publication Date
IL156339A0 true IL156339A0 (en) 2004-01-04

Family

ID=22963185

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15633901A IL156339A0 (en) 2000-12-08 2001-12-06 Indazolyl-substituted pyrroline compounds as kinase inhibitors

Country Status (25)

Country Link
US (4) US6849643B2 (da)
EP (1) EP1362047B1 (da)
JP (1) JP2004515499A (da)
KR (1) KR20040016828A (da)
CN (1) CN1230434C (da)
AT (1) ATE326464T1 (da)
AU (1) AU2002230727A1 (da)
BR (1) BR0116468A (da)
CA (1) CA2431166A1 (da)
CY (1) CY1106125T1 (da)
CZ (1) CZ20031594A3 (da)
DE (1) DE60119790T2 (da)
DK (1) DK1362047T3 (da)
ES (1) ES2263681T3 (da)
HU (1) HUP0303855A3 (da)
IL (1) IL156339A0 (da)
MX (1) MXPA03005140A (da)
NO (1) NO20032625L (da)
NZ (1) NZ526356A (da)
PL (1) PL362576A1 (da)
PT (1) PT1362047E (da)
RU (1) RU2003117078A (da)
WO (1) WO2002046183A2 (da)
YU (1) YU46603A (da)
ZA (1) ZA200305239B (da)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2003117078A (ru) * 2000-12-08 2004-12-10 Орто-Макнейл Фармасьютикал, Инк. (Us) Индазолил-замещенные соединения пирролина в качестве ингибиторов киназы
MXPA04004026A (es) * 2001-10-29 2004-07-08 Nektar Therapeutics Al Corp Conjugados polimericos de inhibidores de la proteina quinasa c.
CN1312154C (zh) 2002-03-05 2007-04-25 伊莱利利公司 作为激酶抑制剂的嘌呤衍生物
MXPA04008671A (es) 2002-03-08 2004-12-06 Lilly Co Eli Derivados de pirrol-2,5-diona y su uso como inhibidores de gsk-3.
ES2300573T3 (es) * 2002-05-08 2008-06-16 Janssen Pharmaceutica Nv Inhibidores de cinasa sustituidos con pirrolina.
JP2005531607A (ja) 2002-06-05 2005-10-20 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ キナーゼ阻害剤として置換ピロリン
CA2520590A1 (en) * 2003-03-27 2004-11-04 Janssen Pharmaceutica, N.V. Substituted pyrroline kinase inhibitors
EA200600032A1 (ru) * 2003-06-13 2006-06-30 Янссен Фармацевтика Н.В. Замещённые производные индазолил (индолил) малеимида в качестве ингибиторов киназ
US7226941B2 (en) * 2003-06-30 2007-06-05 Hif Bio, Inc. Compound for treating angiogenesis
CA2538999A1 (en) * 2003-09-19 2005-03-31 Children's Hospital Medical Center Regulation of cardiac contractility and heart failure propensity
CN1856475A (zh) * 2003-09-23 2006-11-01 默克公司 异喹啉钾通道抑制剂
US20080195033A1 (en) * 2004-11-23 2008-08-14 International Bio-Therapeutic Research Inc. Method of Delivery of Therapeutic Metal Ions, Alloys and Salts
US8017395B2 (en) 2004-12-17 2011-09-13 Lifescan, Inc. Seeding cells on porous supports
RU2007130152A (ru) 2005-01-10 2009-02-20 Астразенека Аб (Se) Производные 1, 1-диоксидов изотиазол-3(2h)-онов в качестве модуляторов печеночных х-рецепторов
SE0500055D0 (sv) 2005-01-10 2005-01-10 Astrazeneca Ab Therapeutic agents 3
SE0500058D0 (sv) * 2005-01-10 2005-01-10 Astrazeneca Ab Therapeutic agents 5
BRPI0606281A2 (pt) * 2005-03-17 2009-06-09 Novartis Ag compostos orgánicos
AU2006255183B2 (en) 2005-06-08 2012-02-02 Centocor, Inc. A cellular therapy for ocular degeneration
WO2007008514A2 (en) * 2005-07-07 2007-01-18 Georgetown University Inhibitors of glycogen synthase kinase 3
EP1940411A4 (en) * 2005-09-29 2008-10-29 Janssen Pharmaceutica Nv MACROHETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS
US8741643B2 (en) 2006-04-28 2014-06-03 Lifescan, Inc. Differentiation of pluripotent stem cells to definitive endoderm lineage
US7741290B2 (en) * 2006-06-01 2010-06-22 The Board of Trustee of The Leland Stanford Juinior University Method of preventing progression of hypertension-induced heart failure with PKC peptides
ES2446269T3 (es) 2006-12-19 2014-03-06 The Board Of Trustees Of The University Of Illinois 3-Benzofuranil-4-indolil-maleimidas como potentes inhibidores de GSK-3 para trastornos neurodegenerativos
MX2009008439A (es) * 2007-02-12 2009-08-13 Intermune Inc Nuevos inhibidores de la replicacion del virus de hepatitis c.
US9080145B2 (en) 2007-07-01 2015-07-14 Lifescan Corporation Single pluripotent stem cell culture
CA2695225C (en) 2007-07-31 2021-06-01 Lifescan, Inc. Differentiation of human embryonic stem cells to pancreatic endocrine
US9062290B2 (en) 2007-11-27 2015-06-23 Lifescan, Inc. Differentiation of human embryonic stem cells
BRPI0908033A2 (pt) 2008-02-21 2015-08-04 Centocor Ortho Biotech Inc Método placas de superfície modificada e composições para adesão, cultura e desprendimento de célula
US8623648B2 (en) * 2008-04-24 2014-01-07 Janssen Biotech, Inc. Treatment of pluripotent cells
BRPI0914116A2 (pt) 2008-06-30 2019-09-17 Centocor Ortho Biotech Inc diferenciação de células-tronco pluripotentes
EP2346988B1 (en) 2008-10-31 2017-05-31 Janssen Biotech, Inc. Differentiation of human embryonic stem cells to the pancreatic endocrine lineage
BRPI0919883A2 (pt) 2008-10-31 2015-08-11 Centocor Ortho Biotech Inc Diferenciação de células-tronco embrionárias humanas para a linhagem endócrina pancreática
CN102257132B (zh) 2008-11-20 2014-09-03 森托科尔奥索生物科技公司 用于在平面基底上进行细胞附着和培养的方法和组合物
ES2642070T3 (es) 2008-11-20 2017-11-15 Janssen Biotech, Inc. Cultivo de células madre pluripotentes en microportadores
AU2010276402B2 (en) 2009-07-20 2014-07-03 Janssen Biotech, Inc. Differentiation of human embryonic stem cells
AU2010276440B2 (en) 2009-07-20 2014-07-03 Janssen Biotech Inc. Differentiation of human embryonic stem cells
BR112012001480A2 (pt) 2009-07-20 2015-09-01 Janssen Biotech Inc Diferenciação de células-tronco embriônicas humanas
WO2011079017A2 (en) 2009-12-23 2011-06-30 Centocor Ortho Biotech Inc. Differentiation of human embryonic stem cells
EP2516626B1 (en) 2009-12-23 2017-05-10 Janssen Biotech, Inc. Differentiation of human embryonic stem cells
WO2011109279A2 (en) 2010-03-01 2011-09-09 Centocor Ortho Biotech Inc. Methods for purifying cells derived from pluripotent stem cells
JP2013526542A (ja) 2010-05-12 2013-06-24 アッヴィ・インコーポレイテッド キナーゼのインダゾール阻害薬
EP3498825A1 (en) 2010-05-12 2019-06-19 Janssen Biotech, Inc. Differentiation of human embryonic stem cells
RU2673946C1 (ru) 2010-08-31 2018-12-03 Янссен Байотек, Инк. Дифференцирование плюрипотентных стволовых клеток
ES2659393T3 (es) 2010-08-31 2018-03-15 Janssen Biotech, Inc. Diferenciación de células madre embrionarias humanas
US9506036B2 (en) 2010-08-31 2016-11-29 Janssen Biotech, Inc. Differentiation of human embryonic stem cells
EP2794857A4 (en) 2011-12-22 2015-07-08 Janssen Biotech Inc DIFFERENTIATION OF HUMAN EMBRYONIC STEM CELLS IN SINGLE INSULIN POSITIVE CELLS
HK1206058A1 (en) 2012-03-07 2015-12-31 Janssen Biotech, Inc. Defined media for expansion and maintenance of pluripotent stem cells
ES2897649T3 (es) 2012-06-08 2022-03-02 Janssen Biotech Inc Diferenciación de células madre embrionarias humanas en células endocrinas pancreáticas
CA2892927A1 (en) * 2012-12-10 2014-06-19 Centogene Ag Use of maleimide derivatives for preventing and treating leukemia
RU2687379C2 (ru) 2012-12-31 2019-05-13 Янссен Байотек, Инк. Суспендирование и кластеризация плюрипотентных клеток человека с целью их дифференцировки в панкреатические эндокринные клетки
EP4219683A1 (en) 2012-12-31 2023-08-02 Janssen Biotech, Inc. Differentiation of human embryonic stem cells into pancreatic endocrine cells using hb9 regulators
AU2013368221B2 (en) 2012-12-31 2018-11-01 Janssen Biotech, Inc. Culturing of human embryonic stem cells at the air-liquid interface for differentiation into pancreatic endocrine cells
US10370644B2 (en) 2012-12-31 2019-08-06 Janssen Biotech, Inc. Method for making human pluripotent suspension cultures and cells derived therefrom
CA2949056C (en) 2014-05-16 2025-10-07 Janssen Biotech, Inc. USE OF SMALL MOLECULES TO IMPROVE MAFA GENE EXPRESSION IN PANCREATIC ENDOCRINE CELLS
GB201509885D0 (en) * 2015-06-08 2015-07-22 Ucb Biopharma Sprl Therapeutic agents
MA45479A (fr) 2016-04-14 2019-02-20 Janssen Biotech Inc Différenciation de cellules souches pluripotentes en cellules de l'endoderme de l'intestin moyen
US11066419B2 (en) 2016-12-30 2021-07-20 Frequency Therapeutics, Inc. 1H-pyrrole-2,5-dione compounds and methods of using same
US10383881B2 (en) 2016-12-30 2019-08-20 Frequency Therapeutics, Inc. 1,5-dihydro-2H-pyrrol-2-one compounds and methods of using same
KR20210125471A (ko) 2018-10-05 2021-10-18 안나푸르나 바이오, 인코포레이티드 Apj 수용체 활성과 관련된 병태를 치료하기 위한 화합물 및 조성물
EP3920885A1 (en) 2019-02-08 2021-12-15 Frequency Therapeutics, Inc. Valproic acid compounds and wnt agonists for treating ear disorders
CN119874775A (zh) 2020-02-07 2025-04-25 加舒布鲁姆生物公司 杂环glp-1激动剂
KR20250168210A (ko) 2023-02-16 2025-12-02 가셔브룸 바이오, 인크. 헤테로시클릭 glp-1 효능제

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ227850A (en) * 1988-02-10 1991-11-26 Hoffmann La Roche Indole substituted pyrrole derivatives; preparatory process and medicaments for use against inflammatory immunological, bronchopulmonary or vascular disorders
MC2096A1 (fr) 1989-02-23 1991-02-15 Hoffmann La Roche Pyrroles substitues
GB8904161D0 (en) 1989-02-23 1989-04-05 Hoffmann La Roche Substituted pyrroles
DE4005969A1 (de) 1990-02-26 1991-08-29 Boehringer Mannheim Gmbh Neue trisubstituierte pyrrole, verfahren zu ihrer herstellung sowie arzneimittel, die diese verbindungen enthalten
DE4005970A1 (de) 1990-02-26 1991-08-29 Boehringer Mannheim Gmbh Neue trisubstituierte maleinimide, verfahren zu ihrer herstellung sowie arzneimittel, die diese verbindungen enthalten
US5624949A (en) 1993-12-07 1997-04-29 Eli Lilly And Company Protein kinase C inhibitors
AU1339895A (en) 1993-12-23 1995-07-10 Eli Lilly And Company Protein kinase c inhibitors
SE9603283D0 (sv) 1996-09-10 1996-09-10 Astra Ab New compounds
EP1057484A4 (en) 1998-02-23 2002-11-20 Sagami Chem Res INHIBITORS OF CELL DEATH
IL141080A0 (en) 1998-07-30 2002-02-10 Japan Tobacco Inc Disubstituted maleimide derivatives and pharmaceutical compositions containing the same
DE69922526T2 (de) 1998-10-08 2005-06-02 Smithkline Beecham Plc, Brentford 3-(3-chloro-4-hydroxyphenylamino)-4-(2-nitrophenyl)-1h-pyrrol-2,5-dion als glykogen synthase kinase-3 inhibitor (gsk-3)
RU2003117078A (ru) * 2000-12-08 2004-12-10 Орто-Макнейл Фармасьютикал, Инк. (Us) Индазолил-замещенные соединения пирролина в качестве ингибиторов киназы
ES2300573T3 (es) 2002-05-08 2008-06-16 Janssen Pharmaceutica Nv Inhibidores de cinasa sustituidos con pirrolina.
JP2005531607A (ja) 2002-06-05 2005-10-20 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ キナーゼ阻害剤として置換ピロリン
US6987110B2 (en) 2002-06-05 2006-01-17 Janssen Pharmaceutica N.V. Substituted pyrrolines as kinase inhibitors
CA2520590A1 (en) 2003-03-27 2004-11-04 Janssen Pharmaceutica, N.V. Substituted pyrroline kinase inhibitors
EA200600032A1 (ru) * 2003-06-13 2006-06-30 Янссен Фармацевтика Н.В. Замещённые производные индазолил (индолил) малеимида в качестве ингибиторов киназ

Also Published As

Publication number Publication date
DE60119790T2 (de) 2007-01-25
NO20032625L (no) 2003-08-05
US7855203B2 (en) 2010-12-21
MXPA03005140A (es) 2004-10-15
ES2263681T3 (es) 2006-12-16
EP1362047B1 (en) 2006-05-17
US20030055097A1 (en) 2003-03-20
CA2431166A1 (en) 2002-06-13
US7329657B2 (en) 2008-02-12
PT1362047E (pt) 2006-09-29
NZ526356A (en) 2005-02-25
EP1362047A2 (en) 2003-11-19
KR20040016828A (ko) 2004-02-25
PL362576A1 (en) 2004-11-02
US7304060B2 (en) 2007-12-04
JP2004515499A (ja) 2004-05-27
ZA200305239B (en) 2004-10-07
AU2002230727A1 (en) 2002-06-18
HK1057370A1 (en) 2004-04-02
US20050004202A1 (en) 2005-01-06
CZ20031594A3 (cs) 2004-06-16
DK1362047T3 (da) 2006-09-04
US20040259928A1 (en) 2004-12-23
CN1489586A (zh) 2004-04-14
US20080096949A1 (en) 2008-04-24
WO2002046183A3 (en) 2002-09-06
ATE326464T1 (de) 2006-06-15
US6849643B2 (en) 2005-02-01
RU2003117078A (ru) 2004-12-10
YU46603A (sh) 2006-05-25
CN1230434C (zh) 2005-12-07
BR0116468A (pt) 2004-06-29
HUP0303855A3 (en) 2005-04-28
HUP0303855A2 (hu) 2004-03-01
CY1106125T1 (el) 2011-06-08
NO20032625D0 (no) 2003-06-10
DE60119790D1 (de) 2006-06-22
WO2002046183A2 (en) 2002-06-13

Similar Documents

Publication Publication Date Title
IL156339A0 (en) Indazolyl-substituted pyrroline compounds as kinase inhibitors
AU2737102A (en) Macroheterocylic compounds useful as kinase inhibitors
AU2003225295A1 (en) Substituted pyrroline kinase inhibitors
AU2003240517A1 (en) Substituted pyrrolines as kinase inhibitors
MXPA03011907A (es) Fluoropirrolidinas como inhibidores de dipeptidil peptidasa.
BG106585A (en) Kinase inhibitors as therapeutic agents
YU84603A (sh) Novi inhibitori tirozin kinaze
AU5584901A (en) Use of cyclic gmp-specific phosphodiesterase inhibitors for treatment of parkinson's disease
MXPA04001891A (es) Inhibidores policiclicos de guanina fosfodiesterasa v.
WO2003002530A3 (en) Pyrrolidines as dipeptidyl peptidase inhibitors
AU3741801A (en) Substituted beta-carbolines with ikb-kinase inhibiting activity
WO2001064676A3 (en) INHIBITORS OF p38-α KINASE
WO2004030620A3 (en) Novel tyrosine kinase inhibitors
ZA200404752B (en) 6-aminomorphinane derivatives method for the production and use thereof
MXPA04002282A (es) Nuevos compuestos y preparaciones como inhibidores de la catepsina.
MX9801190A (es) Inhibidores de prolil endopeptidasa.
WO2002051848A3 (de) Sulfamidothienopyrimidine zur verwendung als phosphodiesterase v-hemmer
MXPA04000446A (es) 4-aminociclohexanoles sustituidos.
YU22802A (sh) Izonipekotamidi za lečenje poremećaja nastalih posredstvom integrina
EP1496907A4 (en) Tyrosine kinase inhibitor
DE50006244D1 (en) Neue substituierte 3-phenoxy- und 3-phenylalkyloxy-2-phenyl-propylamine
EP1496898A4 (en) Tyrosine kinase inhibitor
HU0001287D0 (en) New intermediate and process for its production